Unravelling the underlying mechanisms of Eye Movement Desensitization and Reprocessing (EMDR) therapy: The effects of beta-blocker Propranolol on EMDR effectiveness.

The role of noradrenaline (NA) in Eye Movement Desensitization and Reprocessing (EMDR). Part I: The effects of NA-antagonist propranolol on the plasticity of emotionally arousing episodic memories.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON22254

Enrollment

Registered

2012-11-08

Start date

2013-02-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Propranolol

Interventions

1. Propranolol 40 mg or placebo

2. Memory recall + eye movements, memory recall only.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Passing the medical screening (blood pressure and heart rate examination, two-step test and interview); 2. Age 18-35.

Exclusion criteria

Exclusion criteria: 1. History of cardiovascular problems; 2. Liver or kidney disease; 3. Asthmatic disease; 4. Use of contraindicative medication; 5. History of psychiatric disorders; 6. History of neurological disorders; 7. Hypersensitivity to propranolol; 8. Pregnancy.

Design outcomes

Primary

Measure	Time frame
The emotionality and vividness of recollected memories at pretest (baseline), posttest (after medication intake and each experimental manipulation) and after 24 hour follow-up measured with corrugator EMG, HR, SC, a VAS for emotionality, and a VAS for vividness.	—

Contacts

Public ContactM. Littel

Utrecht University Faculty of Social Sciences Dep. Clinical & Health psychology Heidelberglaan 1

m.littel@uu.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)